Coenzyme Q10 (CoQ10) is a naturally occurring antioxidant that has attracted interest as a potential supplement for non-alcoholic fatty liver disease (NAFLD). Whilst small research studies suggest CoQ10 may help reduce oxidative stress and inflammation in liver cells, it is important to understand that CoQ10 is not licensed by the MHRA for treating fatty liver disease and is not recommended by NICE as a standard therapy. The evidence base remains limited, and CoQ10 should not replace established medical management and lifestyle modifications, which remain the cornerstone of NAFLD treatment in the UK.

What Is Coenzyme Q10 and How Does It Work?

Coenzyme Q10 (CoQ10), also known as ubiquinone, is a naturally occurring compound found in virtually every cell of the human body. It plays a crucial role in the mitochondria—the cellular powerhouses—where it facilitates the production of adenosine triphosphate (ATP), the primary energy currency of cells. Beyond energy production, CoQ10 functions as a potent antioxidant, protecting cells from oxidative damage caused by free radicals.

The body produces CoQ10 naturally, with the highest concentrations found in organs with high metabolic demands, such as the heart, liver, and kidneys. However, CoQ10 levels decline with age and may be reduced in certain medical conditions or through the use of specific medications, particularly statins (though the clinical significance of this reduction remains uncertain). This has led to interest in CoQ10 supplementation for various health conditions.

In the context of fatty liver disease, researchers have investigated CoQ10's potential therapeutic effects based on its antioxidant and anti-inflammatory properties. Non-alcoholic fatty liver disease (NAFLD)—increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD) in international literature, though NAFLD remains the term used in current UK guidance—is characterised by excessive fat accumulation in liver cells, often accompanied by oxidative stress and inflammation. The theory is that CoQ10 supplementation might help reduce oxidative damage to liver cells, potentially improving liver function and reducing inflammation.

Whilst small research studies have shown some promise, it is important to note that CoQ10 is not licensed by the MHRA for the treatment of fatty liver disease and is not recommended by NICE as a standard therapy. The evidence base remains limited, and CoQ10 should not be considered a replacement for established medical management and lifestyle modifications recommended in NICE guideline NG49.

Understanding Fatty Liver Disease: Causes and Symptoms

Fatty liver disease encompasses two main categories: non-alcoholic fatty liver disease (NAFLD) and alcohol-related fatty liver disease (ARLD). NAFLD is increasingly common in the UK, with estimates suggesting it affects approximately one in three adults to some degree. It occurs when excess fat accumulates in the liver in people who drink little or no alcohol. The condition exists on a spectrum, ranging from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH)—also termed metabolic dysfunction-associated steatohepatitis (MASH)—which involves inflammation and liver cell damage that can progress to fibrosis, cirrhosis, and liver failure.

Key risk factors for NAFLD include:

• Obesity, particularly central adiposity

• Type 2 diabetes mellitus

• Insulin resistance and metabolic syndrome

• Dyslipidaemia (abnormal cholesterol levels)

• Hypertension

• Polycystic ovary syndrome (PCOS)

The majority of people with fatty liver disease experience no symptoms, particularly in the early stages. The condition is often discovered incidentally during routine blood tests showing elevated liver enzymes (ALT, AST) or during imaging studies performed for other reasons. When symptoms do occur, they are typically non-specific and may include persistent fatigue, discomfort in the upper right abdomen, or a general feeling of malaise.

As the disease progresses to more advanced stages, symptoms may become more pronounced and can include jaundice (yellowing of the skin and eyes), ascites (fluid accumulation in the abdomen), confusion or altered mental state, easy bruising or bleeding, and swelling of the legs. If you experience jaundice, confusion, vomiting blood, black tarry stools, or rapidly worsening abdominal swelling, seek urgent same-day medical assessment by contacting your GP immediately or attending A&E.

NICE guidelines (NG49) recommend that people with suspected or confirmed NAFLD should have their risk of advanced liver fibrosis assessed using non-invasive tests. In primary care, this typically involves calculating a fibrosis risk score such as FIB-4 or NAFLD Fibrosis Score (NFS). NICE also recommends considering the Enhanced Liver Fibrosis (ELF) blood test; a score of 10.51 or above suggests advanced fibrosis and warrants referral to a liver specialist. Those at lower risk should be reassessed periodically—typically every three years for adults—or sooner if risk factors worsen. Contact your GP if you have risk factors for NAFLD so that appropriate assessment and monitoring can be arranged.

Recommended Dosage and How to Take Coenzyme Q10

There is currently no universally agreed dosage of CoQ10 specifically for fatty liver disease, as it is not an established treatment within NHS or NICE guidelines. Research studies investigating CoQ10 in liver health have typically used doses ranging from 100 mg to 300 mg daily, often divided into two doses taken with meals. It is important to note that these doses are derived from small clinical trials, and improvements in clinical outcomes such as liver fibrosis or long-term liver health have not been proven. Some studies have explored higher doses, but these should only be considered under medical supervision.

CoQ10 is a fat-soluble compound, which means it is best absorbed when taken with food containing some fat. Taking your supplement with a meal that includes healthy fats—such as avocado, nuts, olive oil, or oily fish—can enhance absorption and bioavailability. The supplement is available in several forms, including ubiquinone (the oxidised form) and ubiquinol (the reduced, active form). Ubiquinol is often marketed as more readily absorbed, though head-to-head clinical outcome data are limited, and it tends to be more expensive.

Practical considerations when taking CoQ10:

• Take with meals to improve absorption

• Maintain consistency in timing for optimal blood levels

• Store in a cool, dry place away from direct sunlight

• Check expiry dates, as potency may decrease over time

It is essential to consult your GP or a registered healthcare professional before starting CoQ10 supplementation, particularly if you have fatty liver disease or other medical conditions. Self-prescribing supplements without medical guidance can be problematic, as they may interact with prescribed medications or mask underlying health issues that require proper medical investigation and treatment. Your healthcare provider can assess whether CoQ10 is appropriate for your individual circumstances. If you do take CoQ10, monitoring should include assessment of fibrosis risk using validated tools (such as FIB-4, NFS, or ELF) as well as routine liver blood tests, since liver enzymes may be normal even in the presence of significant liver disease.

Potential Side Effects and Safety Considerations

Coenzyme Q10 is generally well tolerated by most people, with a good safety profile established through decades of use. However, as with any supplement, side effects can occur, and certain precautions should be observed. The most commonly reported side effects are mild and gastrointestinal in nature, including nausea, diarrhoea, abdominal discomfort, and loss of appetite. These effects are typically dose-dependent and may resolve by reducing the dose or taking the supplement with food.

Other potential side effects, though less common, include headaches, dizziness, fatigue, and insomnia. If you experience persistent or troublesome side effects, discontinue use and consult your GP. You can also report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Important drug interactions to consider:

• Warfarin and anticoagulants: There is limited evidence from case reports and pharmacological rationale suggesting CoQ10 may reduce the effectiveness of warfarin. If you take warfarin, do not start CoQ10 without discussing it with your GP or anticoagulation clinic, as more frequent INR monitoring may be needed

• Chemotherapy drugs: Some laboratory and animal studies suggest CoQ10 might interfere with certain cancer treatments, though clinical evidence is limited. Always inform your oncology team if you are considering supplements

• Blood pressure medications: CoQ10 may have modest blood pressure-lowering effects; if you take antihypertensive medication, your GP should monitor your blood pressure

• Statins: Whilst statins can reduce CoQ10 levels biochemically, routine CoQ10 supplementation for people taking statins is not recommended by NICE. There is insufficient evidence that CoQ10 prevents or treats statin-associated muscle symptoms. Discuss with your GP if you have concerns

Pregnant or breastfeeding women should avoid CoQ10 supplementation unless specifically recommended by their healthcare provider, as safety data in these populations is limited. Similarly, individuals scheduled for surgery should inform their surgical team about CoQ10 use, as precautionary advice may be given.

People with fatty liver disease often have multiple comorbidities and take several medications. Always inform your GP and pharmacist about all supplements you are taking to avoid potential interactions and ensure safe, coordinated care. CoQ10 sold as a food supplement in the UK is regulated under food law, not as a licensed medicine, so the MHRA does not assess it in the same way as prescription or over-the-counter medicines. Purchasing from reputable UK or EU suppliers that provide third-party testing and quality assurance is advisable.

Other Treatments and Lifestyle Changes for Fatty Liver

Whilst research into CoQ10 for fatty liver continues, the cornerstone of NAFLD management remains lifestyle modification, as recommended by NICE guideline NG49. Evidence consistently demonstrates that weight loss and increased physical activity can significantly improve liver health, reduce liver fat content, and even reverse early-stage disease.

Weight management is paramount. NICE recommends that individuals with NAFLD who are overweight or obese should aim for gradual, sustained weight loss. A weight reduction of 7–10% of body weight is typically needed to achieve histological improvement in NASH and fibrosis, whilst a loss of around 5% can improve liver enzyme levels and reduce steatosis. Weight loss should be gradual and sustainable; crash diets and rapid weight loss (more than 1.5 kg per week) should be avoided, as they can paradoxically worsen liver inflammation. A structured weight loss programme combining dietary changes with increased physical activity is most effective.

Dietary modifications should focus on:

• Reducing intake of refined carbohydrates and added sugars, particularly fructose and sugar-sweetened beverages

• Limiting saturated fats and avoiding trans fats

• Increasing consumption of fruits, vegetables, whole grains, and lean proteins

• Following a Mediterranean-style diet, which has shown particular benefit for liver health

• Adhering to UK Chief Medical Officers' low-risk drinking guidelines (no more than 14 units per week, spread over three or more days, with several alcohol-free days). If you have advanced fibrosis or cirrhosis, abstinence from alcohol is advised

Physical activity recommendations include at least 150 minutes of moderate-intensity aerobic exercise weekly, such as brisk walking, cycling, or swimming. Resistance training twice weekly can also be beneficial. Exercise improves insulin sensitivity and helps reduce liver fat, even independent of weight loss.

Medical management may be appropriate for some patients. Whilst there are currently no medications specifically licensed for NAFLD in the UK, managing associated conditions is crucial. This includes optimising control of type 2 diabetes, treating dyslipidaemia with statins if indicated (statins are safe in NAFLD and can reduce cardiovascular risk), and managing hypertension. Patients with NASH or advanced fibrosis may be considered for clinical trials of emerging therapies.

Regular monitoring and assessment are essential. Your GP should arrange periodic reassessment of fibrosis risk—typically every three years for adults at low risk, or more frequently if risk factors worsen or new symptoms develop. Non-invasive fibrosis risk tools such as FIB-4 or NAFLD Fibrosis Score are used in primary care. NICE recommends considering the Enhanced Liver Fibrosis (ELF) blood test; an ELF score of 10.51 or above indicates a high likelihood of advanced fibrosis and warrants referral to a liver specialist. In secondary care, imaging such as FibroScan (transient elastography) may be used to assess liver stiffness and fat content.

Contact your GP if you develop new or worsening symptoms such as unexplained weight loss, abdominal swelling, jaundice, persistent vomiting, confusion, or easy bruising or bleeding. Seek urgent same-day medical assessment if you experience jaundice with fever or abdominal pain, vomiting blood, black tarry stools, severe confusion, or rapidly increasing abdominal swelling, as these may indicate serious complications requiring immediate specialist care.

Frequently Asked Questions